Based on the Weekly, I want to get involved on this. I am waiting on a pullback before I get in though:
VRX could be facing some serious legal troubles coming up with this insider trading case, anyone have an opinion on where the stock is going from here? Moving sideways for sometime now, we believe a major correction is due soon, Blue Horsehoe does not love VRX.
A good example of a company with high leverage is Valeant Pharmaceuticals International Inc. VRX, -1.80% Although the drug maker has paid down debt maturing in the near term, some of that was done by borrowing more money. The junk-rated company still has over $27 billion in debt, with leverage well above “ideal” levels, according to J.P. Morgan.
hate these freaking analysts - have been holding this since 11/17 for $30 BUT sold @ $20.>> Is This the End of the Valeant Rally? https://www.barrons.com/articles/is-this-the-end-of-the-valeant-rally-1516808961
Much better position than 2016 & was just coming back up from a few down days & GS coverage (attack) definitely was not expected by me!! lol
NEW YORK (AP) — Valeant Pharmaceuticals, which fell under withering scrutiny after acquiring the rights to drugs and then drastically raising their prices, is changing its name. The Canadian company said Tuesday that it will be called Bausch Health Companies Inc. starting in July. CEO Joseph Papa said in a prepared statement that the name change is "a major step forward" in the company's transformation. Valeant Pharmaceuticals International Inc. fell into the crosshairs of Washington a couple years ago after an extended acquisition spree of other companies, followed by triple-digit price hikes on critical heart drugs and other medicines. Its spate of acquisitions and soaring revenue propelled its stock through the roof, but it ran up a staggering $30 billion in debt — roughly three times its annual revenue. Former CEO Michael Pearson, who formulated the strategy, w
